Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

General Hospital Of Larissa Koutlibaneio And Triantafylleio

Research site

Greece Tsakalof 1, 412 21 Larissa, Greece

  • 2 trials recruiting
  • Sickle cell disease · Thalassaemia alpha · Bacterial infection
  • Adults and children

About Specializations

General Hospital Of Larissa Koutlibaneio And Triantafylleio in Larissa, Greece specialises in clinical trials of conditions such as Sickle cell disease, Thalassaemia alpha, Bacterial infection, Myelodysplastic syndrome/myeloproliferative neoplasm overlap syndrome, and other specialisations. This site conducts important research.

Main research areas of the site

Therapeutics

The department is evaluating innovative drug candidates to improve outcomes for patients with sickle cell disease and transfusion‑dependent thalassemia, as well as therapies for severe hospital‑acquired pneumonia.

  • Novel oral activators targeting hemoglobin function
  • Combination regimens for hydroxyurea‑non‑eligible patients
  • Dose‑finding studies in myelodysplastic syndrome cohorts

Research conducted at General Hospital Of Larissa Koutlibaneio And Triantafylleio showcases a commitment to advancing therapeutic options for hematologic disorders.

Bacterial Infections and Mycoses

Trials aim to reduce mortality from hospital‑acquired pneumonia and sepsis through early, biomarker‑guided antibiotic strategies.

  • PSP‑guided early meropenem administration
  • Dexamethasone added to standard care for inflammatory pneumonia
  • Evaluation of pro‑inflammatory phenotypes as trial endpoints

The site’s focus on rapid infection management reflects its expertise in acute care within the Larissa region.

Eye Diseases

A non‑inferiority study compares a preservative‑free brimonidine/timolol eye‑drop formulation with the standard product for patients with open‑angle glaucoma.

  • Intra‑ocular pressure reduction at 08:00
  • Safety and tolerability of preservative‑free solution
  • Patient‑reported comfort and adherence

The department’s ophthalmic research complements its hematology program, offering comprehensive care at the hospital.

Hemic and Lymphatic Diseases

Clinical investigations target the underlying mechanisms of hemoglobinopathies and related marrow disorders, seeking to lessen transfusion burden.

  • Long‑term safety of etavopivat across sickle cell and thalassemia populations
  • Dose‑response evaluation of SP‑420 in transfusion‑dependent patients
  • Assessment of quality‑of‑life improvements

General Hospital Of Larissa’s hematology unit leverages multidisciplinary expertise to address complex blood diseases.

Pathological Conditions, Signs and Symptoms

Research also addresses clinical signs such as elevated intra‑ocular pressure and systemic inflammatory markers to refine diagnostic and monitoring tools.

  • Monitoring IOP changes in glaucoma therapy trials
  • Use of qSOFA and NEWS2 scores for early sepsis detection
  • Correlation of PSP levels with infection risk

These studies highlight the site’s dedication to integrating diagnostic precision with therapeutic innovation.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Site location
Tsakalof 1412 21 LarissaGreece
Open in maps ↗
Recruiting now
2 trials
Conditions studied
11

More sites in LarissaGreece

Recruiting now

Ongoing trials

Clinical trials currently enrolling participants at this site.

Condition
Type of trial
Recruitment status
Quick filters

9 clinical trials

Sickle cell disease+1

Recruiting

Long-term safety study of oral etavopivat tablets in children, adolescents and adults with sickle cell disease or thalassaemia who completed previous etavopivat treatment

InvestigationalNo placebo
Countries:GreeceGreece
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Etavopivat
  • Sponsor:Novo Nordisk A/S

Thalassaemia beta+2

Recruiting

Study of SP-420 for Patients with Transfusion-Dependent Alpha or Beta Thalassemia

InvestigationalNo placebo
Countries:GreeceGreece
  • Participants:18–64 years
  • Substances:(S)-4,5-Dihydro-2-[2-Hydroxy-4-(3,6-Dioxaheptyloxy)Phenyl]-4-Methyl-4-Thiazolecarboxylic Acid
  • Sponsor:Pharmacosmos A/S

Rhinitis

Not yet recruiting

Randomized study of ketotifen nasal spray (0.025% and 0.050%) versus sodium cromoglicate nasal spray in patients with rhinitis

Registered drug
Countries:GreeceGreece
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Sodium Cromoglicate

Bacterial infection+1

Not yet recruiting

A study to evaluate the use of meropenem to reduce the risk of sepsis in patients with suspected infection in the emergency department

Registered drug
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:Meropenem Anhydrous
  • Sponsor:Hellenic Institute For The Study Of Sepsis

Pneumonia

Not recruiting

Study on Dexamethasone and Sodium Chloride for Treating Severe Hospital-Acquired Pneumonia in Critically Ill Patients with a Proinflammatory Profile

Registered drug
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:Sodium Chloride
  • Sponsor:Centre Hospitalier Universitaire De Nantes

Open angle glaucoma+1

Not recruiting

Study Comparing Brimonidine and Timolol Eye Drops for Patients with Open-Angle Glaucoma or Ocular Hypertension

Registered drugNo placebo
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:Brimonidine Tartrate
  • Sponsor:Becro (Cyprus) Limited

Sickle cell disease

Not recruiting

Study on the Effectiveness of Decitabine and Tetrahydrouridine in Patients with Sickle Cell Disease Not Eligible for Hydroxyurea Treatment

Registered drug
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:Decitabine
  • Sponsor:Novo Nordisk A/S

Sickle cell disease

Not recruiting

Study on the Effects of Etavopivat for Patients Aged 12-65 with Sickle Cell Disease

Investigational
Countries:GreeceGreece
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Etavopivat
  • Sponsor:Novo Nordisk A/S

Thalassaemia alpha

Not recruiting

Study on Luspatercept for Treating Anemia in Adults and Adolescents with Alpha-Thalassemia

Registered drug
Countries:GreeceGreece
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Luspatercept
  • Sponsor:Celgene Corp.
Is this your site?

Join our network of research sites

Get verified: confirm your contact details and recruitment status with us, appear first on the pages of your trials and receive patient requests directly.

See the offer for sites
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.